GLP-1 medicines are not established treatments for BED
GLP-1 medicines have been studied for binge eating disorder (BED), but the evidence is preliminary. Their effects on appetite do not establish that they treat an eating disorder. In a small randomized liraglutide trial, binge episodes decreased in both treatment groups, and the difference from placebo was not statistically significant.
The U.S. labels for Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide) do not include BED as an indication. Research into these medicines should not delay an eating-disorder assessment or be presented as a reason to seek an off-label prescription.
Recognizing binge eating disorder
BED involves recurrent episodes of eating an unusually large amount within a limited time while feeling a loss of control, with significant distress. Episodes may involve eating rapidly, eating beyond comfortable fullness, eating alone out of embarrassment, or feeling ashamed afterward.
The diagnostic pattern includes episodes at least weekly for three months. Unlike bulimia nervosa, BED is not characterized by regular compensatory behaviors such as vomiting, fasting, or excessive exercise. A clinician should assess any such behaviors rather than relying on a self-diagnosis.
BED can occur at any body size. Occasional overeating, strong hunger, or thinking about food often is not enough to diagnose it. You do not need to wait until symptoms meet a diagnostic threshold to ask for help.
What the studies actually found
The liraglutide pilot trial did not establish a binge-eating benefit
The Allison and colleagues pilot randomized trial included 27 adults with BED and BMI of at least 27, followed over 17 weeks.
| Outcome | Liraglutide group | Placebo group | Interpretation |
|---|---|---|---|
| Average reduction in objective binge episodes per week | 4.0 | 2.5 | Between-group difference was not statistically significant; p = 0.37 |
| BED remission | 44% | 36% | No statistically significant difference |
| Average percentage weight loss | 5.2% | 0.9% | Weight difference was statistically significant, but this was not proof of BED remission |
The researchers also reported a pharmacy dispensing error as a major limitation. The small sample and short follow-up limit the conclusions. This trial does not support a claim that liraglutide reliably cuts binge eating by a specific percentage, and weight loss should not be substituted for the primary eating-disorder outcome.
Semaglutide findings came from a retrospective chart review
A 2023 study by Richards and colleagues examined records from an obesity medicine and bariatric surgery clinic. Its main analysis involved 48 patients with questionnaire scores suggesting moderate-to-severe binge-eating symptoms.
Patients receiving semaglutide had larger reductions in Binge Eating Scale scores than patients receiving certain other medicines. But treatment was not randomly assigned, the study was open-label, and a symptom questionnaire is not the same measure as independently assessed binge episodes or sustained remission.
Those findings justify controlled research. They do not establish that semaglutide is superior to approved BED treatment, that combinations are safe or necessary, or that results extend to people outside that clinic population. Nor can findings for one medicine establish a benefit for tirzepatide.
Appetite changes are not the same as recovery
GLP-1 medicines affect appetite and gastric emptying. Researchers are also investigating brain pathways involved in eating and reward. A proposed mechanism is not a demonstrated treatment effect.
Someone may report less “food noise” while still struggling with loss of control, distress, restriction, or body-image concerns. Someone else may recover from binge eating without losing weight. Useful outcomes include fewer loss-of-control episodes, more regular eating, less distress, adequate nutrition, and improved daily functioning.
The trials above do not prove that adding a GLP-1 medicine to cognitive behavioral therapy is better than therapy alone. Claims about that combination need their own evidence.
Established care should remain accessible
NICE's eating-disorder guideline recommends BED-focused guided self-help for adults, with eating-disorder-focused cognitive behavioral therapy when needed. It advises against medication as the sole treatment for BED. Psychological therapy is not “FDA-approved”; the FDA regulates medicines and devices, not therapy approaches.
Vyvanse (lisdexamfetamine) has a U.S. indication for moderate-to-severe BED in adults. It is a prescription stimulant with risks, including misuse and dependence, and is not appropriate for everyone. A clinician should assess treatment options rather than treating it as an automatic next step or a weight-loss drug.
During BED treatment, regular meals and snacks can help address hunger. NICE advises against dieting to lose weight during treatment because it can trigger binge eating. A restrictive meal plan, portion-control product, or appetite-suppression target should not replace an individualized nutrition plan from an eating-disorder-informed team.
If you already take a GLP-1 for another condition
Tell the prescriber about current or past eating disorders, purging, prolonged fasting, or fear of eating. Coordinate diabetes or obesity care with the clinician treating the eating disorder. Do not independently alter your prescription or discontinue another treatment because appetite has changed.
Ask for reassessment if you develop:
- Increasing restriction, skipped meals, or difficulty meeting nutritional needs.
- New or worsening binge episodes, purging, or compulsive exercise.
- Persistent nausea or vomiting that interferes with regular eating.
- Increasing anxiety, shame, or preoccupation with weight and food.
Fainting, severe dehydration, inability to keep fluids down, or severe persistent abdominal pain needs urgent medical evaluation. Breathing difficulty or facial or throat swelling needs emergency care. Seek immediate help for thoughts of self-harm or inability to stay safe, regardless of whether medication is involved.
What to discuss at an appointment
Describe the loss of control and distress, not just what you ate or your weight. Ask for an eating-disorder assessment, available psychological treatment, and help coordinating any metabolic medication with regular nutrition. Agree on how symptoms and physical safety will be monitored, including what to do if appetite suppression makes eating difficult.
For related education, read GLP-1 side effects and mental health and body image.
This article is general education, not a diagnosis or recommendation to use GLP-1 medicines off-label for BED.
